3 Reasons to Buy This Biotech Stock

MGTA is assailing new heights after Raymond James initiated coverage

Mar 15, 2019 at 3:00 PM
facebook twitter linkedin


Magenta Therapeutics Inc (NASDAQ:MGTA) is among the best Nasdaq stocks today, thanks to some upbeat analyst attention. Specifically, Raymond James launched coverage of the biotech stock with an "outperform" rating and $22 price target -- representing a 60% premium to Thursday's close. The analyst gave three reasons for the bullish initiation: encouraging clinical results -- and "an opportunity to significantly increase the utilization" of -- its MGTA-456 stem cell therapy; the prospects for MGTA-145; and the potential for Magenta's C200 to alleviate headwinds for cell-based gene therapies.

MGTA shares were last seen 27.8% higher at $17.52, and earlier touched an all-time high of $17.95. Today's rally has the stock barreling through former resistance in the $16-$16.50 neighborhood, which has contained most advances since its initial public offering (IPO) -- priced at $15 -- and debut in June.

Considering the shares have more than tripled since their record low of $5.31 on Dec. 28, it's not surprising that most analysts are already bullish on MGTA. The stock currently boasts five "buy" or better ratings, with not a single "hold" or "sell" in sight. However, some price-target hikes could be in store, as the consensus 12-month price target of $20.33 now represents just a 16% premium to current levels.

What's more, a short squeeze could be in effect. Short interest accounts for more than 5% of MGTA's total available float, representing more than three weeks' of pent-up buying demand, at the security's average pace of trading.

 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners